Skip to main content
Premium Trial:

Request an Annual Quote

CuraGen Reports Smaller Revenues, Higher Losses and a New Toxicogenomics Deal

NEW YORK, Oct. 24-CuraGen today reported slightly smaller revenues and sharply higher net losses for the third quarter of 2002.


The company's loss was $19.9 million for the quarter, or 41 cents per share. For the third quarter of 2001, the company's loss was $11.1 million or 23 cents per share.


Revenues for the quarter were $6 million, down from $6.1 million during the equivalent period last year.


The company spent $21.3 million on R&D this past quarter, up from $17.4 million during the third quarter of 2001.


For further details, see the press release.


CuraGen also announced a new partnership yesterday in which Ono Pharmaceutical will use its genomics-based toxicology screen to evaluate drug compounds.


In an agreement that builds upon a pharmacogenomics deal the two companies struck in 2000, the Japanese pharmaceutical company will use CuraGen's system evaluate and rank early-stage compounds.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.